NeuroMab™ Anti-Tau40 BBB Shuttle Antibody(NRZP-1022-ZP3061)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Chimeric

Applications

WB; ELISA; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

Tau40

Official Name

MAPT

Alternative Names

MAPT; DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; PPND; PPP1R103; TAU; microtubule associated protein tau; Tau proteins

Product Pictures

ELISA

Figure 1 ELISA measuring ch17C1, ch17C1(N31Q) mIgG2a and ch17C1(N31Q) mIgG1 in the combination of Agly and recombinant Tau.

ELISA

Figure 2 ELISA measurements of ch17C1(N31Q) mIgG2a and ch17C1(N31Q, I48V).

FuncS

Figure 3 Pathological aggregation of Tau protein in vivo and in brains of AD and tauopathies transgenic mice.

FuncS

Figure 4 shows TauP301L treated with ch17C1(N31Q) and ch4E4(N30Q), Western blotting to detect soluble and insoluble human tau in mice.

FuncS

Figure 5 application ch17C1 (N31Q) and ch4E4 (N30Q) 24 hours after the last administration of peritoneal animal mean plasma drug concentration. Mean plasma drug concentrations of ch17C1 (N31Q) and ch4E4 (N30Q) were 145 and 200 μg/mL, respectively.